Thorne HealthTech

Thorne HealthTech, Inc. is engaged in the provision of a total system for wellness. It utilizes testing and data to create improved product quality and deliver personalized solutions to consumers, health professionals, and professional sports teams. It also helps pharmaceutical and biotechnology companies repurpose existing drugs and compounds, improve existing medications and develop new products. The company was founded by Paul Jacobson in 2010 and is headquartered in New York, NY.

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Thorne HealthTech (THRN) CEO Paul Jacobson on Q4 2021 Results- Earnings Call Transcript

Provides Full-Year 2022 Guidance NEW YORK , March 14, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or the "Company") (NASDAQ: THRN), a leader in developing personalized, innovative solutions to help people live healthier, longer lives, today announced its financial results for the fourth quarter and full-year ended December 31, 2021. Fourth Quarter Highlights: Net sales grew 37.8% to $49.9 million, with direct-to-consumer ("DTC") sales growth of 56.1% Gross profit grew 47.5% to $25.7 million; gross margin of 51.5% increased 340 basis points Net income attributable to common stockholders of $3.3 million; adjusted EBITDA of $5.4 million Diluted earnings per share of $0.01; adjusted diluted earnings per share of $0.07 Full-Year Highlights: Net sales grew 33.8% to $185.2 million, with DTC sales growth of 37.7% Gross profit grew 50.3% to $97.4 million; gross margin of 52.6% increased 580 basis points Net income attributable to common stockholders of $3.7 million; adjusted EBITDA of $20.6 million Diluted earnings per share of $0.10; adjusted diluted earnings per share of $0.27 Full-Year 2022 Outlook: Net sales of $240 million to $250 million; adjusted EBITDA of $30 million to $35 million; adjusted EPS of $0.28 to $0.30 "Our strong results reflect the successful execution of our strategies, which we expect to continue driving outperformance in the growing wellness market," said Paul Jacobson, Thorne HealthTech's chairman and CEO.

Thorne HealthTech Reports Fourth Quarter and Full-Year 2021 Results

NEW YORK, March 3, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, today announced it has acquired Nutrativa LLC, an innovative company leveraging two-dimensional ("2D") high-speed printing technology to provide healthier, environmentally superior alternatives to traditional beverages and gummies via dissolvable supplement discs. Terms of the deal were not announced.

Thorne HealthTech Announces the Acquisition of Nutrativa

NEW YORK, Feb. 25, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, will host a conference call on Tuesday, March 15, 2022, at 8 a.m. (U.S. Eastern Time) to discuss its fourth quarter and full-year 2021 financial results.

Thorne HealthTech Announces Fourth Quarter and Full-Year 2021 Earnings Conference Call

LAS VEGAS and NEW YORK, Feb. 24, 2022 /PRNewswire/ -- UFC ® , the world's premier mixed martial arts organization, and Thorne Health Tech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, today announced a multi-year extension of their global marketing partnership. Thorne remains the Official Sports Performance Nutrition Partner of UFC and an official partner of the UFC Performance Institute ® , the world's first Mixed Martial Arts (MMA) multi-disciplinary research, innovation, and training center.

UFC® AND THORNE ANNOUNCE MULTI-YEAR EXTENSION OF PARTNERSHIP

Mitsui & Co Ltd

Thorne HealthTech Inc (NASDAQ: THRN) has agreed to form a joint venture with Mitsui & Co Ltd (OTC: MITSY) called Thorne HealthTech Asia Pte. Ltd. (Thorne Asia).

Thorne HealthTech Joins Hand With Mitsui To Form Thorne Asia JV

NEW YORK, Jan. 13, 2022 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or "Thorne") (NASDAQ:THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, today announced it has agreed to form a joint venture with Mitsui & Co., Ltd. ("Mitsui") called Thorne HealthTech Asia Pte.

Thorne HealthTech and Mitsui Announce Thorne Asia Joint Venture

The market oversold Thorne shares. The company is growing at double-digit rates. It has strong positioning and enormous market potential.

Thorne HealthTech: Good Potential At A Low Price

Thorne HealthTech Inc (NASDAQ: THRN) has signed a multi-year partnership with a professional cycling team Human Powered Health, formerly known as Rally Cycling. Thorne will serve as the cycling team's Official Personalized Health Solutions Partner.

Thorne HealthTech Inks Multi-Year Partnership With Human Powered Health Cycling Team

NEW YORK, Dec. 14, 2021 /PRNewswire/ -- Thorne HealthTech (NASDAQ: THRN) today announced a new, multi-year partnership with professional cycling team, Human Powered Health, formerly Rally Cycling, in which Thorne will serve as their Official Personalized Health Solutions Partner. The partnership will equip the elite athletes of Human Powered Health with Thorne's best-in-class health testing and nutritional supplements needed to fuel their performance.

Thorne HealthTech Announces Multi-Year Partnership with Professional Cycling Team, Human Powered Health

NEW YORK, Nov. 22, 2021 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or the "Company") (NASDAQ:  THRN ), a leader in developing innovative solutions for a personalized approach to health and wellbeing, will present at the Evercore ISI 4th Annual HealthCONx Conference on Thursday, December 2, 2021. Paul Jacobsen, Thorne HealthTech's Chief Executive Officer, is scheduled to present at 10:30 a.m.

Thorne HealthTech to Present at 4th Annual Evercore ISI HealthCONx Conference

NEW YORK, Nov. 10, 2021 /PRNewswire/ -- Thorne HealthTech, Inc. ("Thorne HealthTech" or the "Company") (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, today announced financial and operational results for the third quarter and nine months ended September 30, 2021. "Our digitally native brand continues to thrive, and our third quarter results are representative of our team's ability to execute against our plan.

Thorne HealthTech Reports Financial and Operating Results for the Third Quarter 2021

NEW YORK, Oct. 25, 2021 /PRNewswire/ -- Thorne HealthTech, Inc. (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, will release third quarter 2021 financial results on Wednesday, November 10, 2021, prior to the market open. In conjunction with the earnings release, Thorne HealthTech's management team will host a conference call at 8:30 a.m.

Thorne HealthTech to Host Third Quarter 2021 Earnings Conference Call

NEW YORK, Sept. 27, 2021 /PRNewswire/ -- Thorne HealthTech (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellbeing, today announced the closing of its initial public offering of 7,000,000 shares of common stock at a price of $10.00 per share, for total gross proceeds for the offering, before deducting the underwriting discounts and other offering expenses, of $70.0 million.

Thorne HealthTech Announces Closing of its Initial Public Offering

Thorne HealthTech Inc (NASDAQ: THRN) has priced its initial public offering (IPO) of 7 million shares of its common stock at $10.00 per share. The company had estimated the IPO price to be $10 - $11 per share.

News for Thorne HealthTech Stock (THRN)